Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Cellectis S.a.

Clinical trials sponsored by Cellectis S.a., explained in plain language.

Cellectis S.A. CLLS NASDAQ

A clinical-stage biopharmaceutical company using gene-editing to develop immunotherapies.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 1

Engineered immune cells take on tough leukemia

Disease control Recruiting now

This study is testing a new treatment called UCART22 for people with a type of blood cancer called B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatments. UCART22 uses donor immune cells that are engineered in a lab to recognize and attack …

Phase: PHASE1, PHASE2 • Sponsor: Cellectis S.A. • Aim: Disease control

Last updated Jun 26, 2026 14:53 UTC